OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) - FOAMIX PHARMACEUTICALS LTD ownership

FOAMIX PHARMACEUTICALS LTD's ticker is FOMX and the CUSIP is M46135105. A total of 69 filers reported holding FOAMIX PHARMACEUTICALS LTD in Q1 2017. The put-call ratio across all filers is 0.15 and the average weighting 0.2%.

Quarter-by-quarter ownership
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) ownership history of FOAMIX PHARMACEUTICALS LTD
ValueSharesWeighting
Q4 2018$274,000,000
-53.0%
76,454
-24.9%
0.01%
-23.1%
Q3 2018$583,000,000
+293.9%
101,800
+239.3%
0.01%
+550.0%
Q1 2017$148,000,00030,0000.00%
Other shareholders
FOAMIX PHARMACEUTICALS LTD shareholders Q1 2017
NameSharesValueWeighting ↓
DSC Advisors, L.P. 1,667,377$15,440,0009.38%
GREAT POINT PARTNERS LLC 2,769,425$25,645,0006.54%
Opaleye Management Inc. 630,000$5,834,0003.05%
Vivo Capital, LLC 855,000$7,917,0002.47%
DAFNA Capital Management LLC 278,067$2,575,0001.79%
RA Capital Management 1,820,138$16,854,0001.74%
SENZAR ASSET MANAGEMENT, LLC 523,397$4,846,656,0001.25%
Perceptive Advisors 1,373,284$12,717,0000.82%
Monashee Investment Management LLC 225,000$2,084,0000.73%
NEXTHERA CAPITAL LP 125,000$1,158,0000.71%
View complete list of FOAMIX PHARMACEUTICALS LTD shareholders